- Sitravatinib plus tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic non-small cell lung cancer (NSCLC)Gao, B.; Ma, Z.; Yu, X.; Huang, D.; Zhao, J.; Day, D.; Body, A. L.; Zhou, Q.; Chu, Q.; Pan, H.; Cui, J.; Li, H.; Sun, J.; Zhang, J.; Fei, C.; Wu, Y-L.ESMO Targeted Anticancer Therapies Congress (TAT), ELECTR NETWORK, 2022-03-07 To 2022-03-08.被引 2
- Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC)Chen, Zhendong; Bai, Yuxian; Zhang, Tao; Ying, Jieer; Lin, Xiaoyan; Yang, Liu; Wang, Jun; Zhang, Juan; Yu, Fan; Fei, Cong; Huang, Ruiqi; Li, JinASCO Gastrointestinal Cancers Symposium, San Francisco, CA, 2022-01-20 To 2022-01-22.被引 1
- Phase (Ph) I/II study of sitravatinib (Sitra) alone or with tislelizumab (TIS) in advanced hepatocellular carcinoma (HCC) and gastric/gastroesophageal junction cancer (GC/ GEJC)Li, J.; Bai, Y.; Chen, Z.; Ying, J.; Guo, Y.; Fang, W.; Zhang, F.; Xiong, J.; Zhang, T.; Meng, Z.; Zhang, J.; Yu, F.; Zhang, J.; Zhang, Z.; Qin, S.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
会议论文
Sitravatinib plus tislelizumab in patients with metastatic non-small cell lung cancer (NSCLC)
7阅读
